Treat for 6-9 months or until 6 months have elapsed from conversion to sputum culture negativity. Pregnancy C - Safety for use during pregnancy has not been established. Treat drug-resistant patients with individualized regimens. Impairs cell metabolism by inhibiting synthesis of one or more metabolites, which in turn causes cell death. No cross-resistance demonstrated.
Mycobacterial resistance is frequent with previous therapy.
Use in these patients in combination with second-line drugs that have not been previously administered. Administer q24h until permanent bacteriological conversion and maximal clinical improvement is seen. Absorption is not significantly altered by food. Pregnancy B - Usually safe but benefits must outweigh the risks. Bilaterally symmetric papulonecrotic lesions on the lower extremity.